BUSINESS

• Xtandi Hits Mark in China HSPC Study to Pave Way for Label Expansion
  March 15, 2023

• Takeda’s Dengue Vaccine Approved in Brazil
  March 15, 2023

• Eisai’s Leqembi Wins Coverage from US Veteran’s Body
  March 15, 2023

• Bayer Setting Out to Cut Up to 480 Jobs as Xarelto Patent Cliff Looms: Employee
  March 14, 2023

• Japan’s Non-COVID Jab Market to Surpass 180 Billion Yen by 2030: Fuji Keizai
  March 14, 2023

• Moderna, Tohoku University Link Up for Next-Gen Healthcare
  March 14, 2023

• Shionogi Inks Malaria Drug Collab with Nagasaki University, MMV
  March 14, 2023

• Serious Side Effect Cases Total 8: Xocova Safety Update
  March 13, 2023

• Padcev Application Accepted for Review in China: Astellas
  March 13, 2023

• AstraZeneca Looks to 1st IO/ADC Launch as Leader in the Race: Oncology Head
  March 13, 2023

• Eisai Eyes 1 Trillion Yen in Leqembi Global Sales in FY2030: CEO
  March 10, 2023

• Xospata Fails in PIII for Post-Transplant AML Maintenance Therapy: Astellas
  March 10, 2023

• Shingo Iwamoto Sworn in as New Chief of Nichi-Iko; Tamura Bows Out
  March 9, 2023

• Silgard 9 Approved for 2-Dose Schedule: MSD
  March 9, 2023

• Nipro Curbed Shipments of 28 APIs/40 Products as Precaution for Rush Demand
  March 9, 2023

• Opdivo Tops Japan Drug Ranking for 14 Months Running: Encise
  March 8, 2023

• Japan Ethical Drug Sales Grow 3.5% in January: Crecon
  March 8, 2023

• Teva Takeda Prepping for Listing of Allermist AG in June
  March 8, 2023

• Kyorin Out-Licenses Vibegron to Sumitomo in 5 Asian Markets
  March 7, 2023

• Azilva, Abraxane, and More Major Meds Get Add-On PMPs under Ad-Hoc Rule in FY2023: Poll
  March 7, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 144
• 145
• 146
• 147
• 148
• 149
• 150
• 151
• 152
• …
• Next ›
• 最終 »